Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus placebo and tiotropium for exercise endurance in moderate to severe COPD
2010-022721-14Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of indacaterol, glycopyrronium and tiotropium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Exercise endurance time during submaximal constant-load cycle ergometry. Started Nov 2010; status: completed.
02
Drugs
indacaterolglycopyrroniumtiotropium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2010-022721-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022721-14.